Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance of $28.4 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $1.81 per share was 2.1% above analysts’ consensus estimates.
Is now the time to buy GILD? Find out in our full research report (it’s free).
Gilead Sciences (GILD) Q1 CY2025 Highlights:
- Revenue: $6.67 billion vs analyst estimates of $6.81 billion (flat year on year, 2.1% miss)
- Adjusted EPS: $1.81 vs analyst estimates of $1.77 (2.1% beat)
- Adjusted EBITDA: $3.16 billion vs analyst estimates of $3.42 billion (47.4% margin, 7.7% miss)
- The company reconfirmed its revenue guidance for the full year of $28.4 billion at the midpoint
- Management reiterated its full-year Adjusted EPS guidance of $7.90 at the midpoint
- Operating Margin: 33.6%, up from -64.6% in the same quarter last year
- Free Cash Flow Margin: 24.8%, down from 31.6% in the same quarter last year
- Market Capitalization: $120.5 billion
StockStory’s Take
Gilead Sciences’ first quarter results reflected growth in its core HIV and liver disease businesses, driven by rising demand for flagship therapies like Biktarvy and the ongoing launch of Libdelzi. Management attributed the company’s performance to commercial execution and highlighted solid operating margin expansion due to disciplined expense management. However, weaker oncology sales and declining COVID-19 treatment demand weighed on overall revenue.
Looking ahead, the company’s guidance centers on an anticipated FDA decision for lenacapavir in HIV prevention, as well as multiple clinical trial readouts for its oncology pipeline. Management reiterated its full-year targets, noting that demand-led volume growth in HIV could be offset by Medicare Part D redesign headwinds. CEO Daniel O’Day emphasized, “We have multiple potential launches ahead…including lenacapavir, anetocel, and now Trodelvy,” pointing to a focus on portfolio diversification and pipeline advancement.
Key Insights from Management’s Remarks
Gilead Sciences’ management pointed to a combination of product launches, market dynamics, and operational discipline as shaping the first quarter and the outlook for the remainder of the year. The company’s base business, excluding COVID-19 treatments, grew due to strong HIV sales and a successful new drug launch in liver disease, even as other therapeutic areas faced challenges.
-
HIV Franchise Expansion: Growth in HIV was buoyed by Biktarvy’s higher demand and market share, along with increased use of Descovy for HIV prevention, reflecting broader awareness and access. Management noted that the upcoming potential launch of lenacapavir for pre-exposure prophylaxis (PrEP) could further expand the company’s presence in HIV prevention.
-
Libdelzi Launch Momentum: The liver disease therapy Libdelzi achieved rapid uptake, securing significant market share in primary biliary cholangitis (PBC) and expanding into Europe. Management cited positive feedback from healthcare providers and robust coverage by commercial insurance plans.
-
Oncology Mixed Results: Trodelvy sales were impacted by inventory fluctuations and lower average prices, but management highlighted strong demand in key breast cancer indications and promising results from the ASCENT-04 study. The trial showed improved progression-free survival, which could support regulatory filings and future growth.
-
Cell Therapy Competitive Pressures: Sales of cell therapies such as Yescarta and Tecartus were affected by increasing competition from both similar cell therapies and emerging bispecific antibody treatments, particularly outside the U.S. The company continues to invest in next-generation products and manufacturing scale.
-
Operating Efficiency and Margin Discipline: Management reported flat product gross margin and reduced selling, general, and administrative (SG&A) expenses, citing ongoing cost controls and a focus on maintaining top-quartile operating margins despite competitive and macroeconomic pressures.
Drivers of Future Performance
Management’s outlook for the rest of the year is shaped by new product launches, policy headwinds in the U.S., and evolving competitive dynamics in oncology and cell therapy.
-
Lenacapavir Approval and Uptake: The anticipated FDA decision for lenacapavir in HIV prevention could drive new patient growth, with management preparing for phased market access and provider adoption over the next 6–12 months.
-
Medicare Part D Redesign Impact: Flat reported HIV sales are expected in 2025 as volume growth is offset by higher manufacturer contributions under the Medicare Part D redesign. Management indicated that any positive impact from improved patient access would likely appear later in the year.
-
Oncology and Cell Therapy Pipeline Readouts: Upcoming clinical data for Trodelvy and anetocel, as well as new CAR-T therapies, remain major swing factors for future revenue, especially as competition intensifies in both established and emerging treatment areas.
Top Analyst Questions
-
Michael Yee (Jefferies): Asked about lenacapavir’s commercial ramp and reimbursement, with management outlining a gradual access build over 6–12 months, expecting 75% coverage by six months post-launch.
-
Carter Gould (Fitzgerald): Queried the impact of federal funding cuts on HIV prevention launches. Management said no changes to plans are anticipated, citing continued engagement with policymakers and support for awareness initiatives.
-
Salveen Richter (Goldman Sachs): Sought clarification on tariff and supply chain exposure, with executives explaining that most intellectual property and manufacturing are U.S.-based, limiting direct tariff impact, and that cost increases have been absorbed in guidance.
-
Tim Anderson (BofA): Asked whether lenacapavir will cannibalize Descovy sales. Management declined to provide product-specific forecasts but indicated a switch from daily orals to long-acting injectables is anticipated in the market.
-
Evan Seigerman (BMO): Inquired about competitive pressures in cell therapy. Management acknowledged both in-class competition and new bispecific treatments as key factors affecting volume outside the U.S.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will closely monitor (1) the U.S. launch and adoption curve for lenacapavir in HIV prevention, (2) clinical trial updates for Trodelvy in breast cancer and anetocel in multiple myeloma, and (3) the company’s ability to navigate the Medicare Part D redesign’s impact on HIV revenues. Progress in expanding Libdelzi’s presence in Europe and evolving competitive dynamics in cell therapy will also be important markers of execution.
Gilead Sciences currently trades at a forward P/E ratio of 11.8×. In the wake of earnings, is it a buy or sell? The answer lies in our free research report.
Stocks That Overcame Trump’s 2018 Tariffs
The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.